Dispatch Bio Showcases SEND-Based T Cell Armoring Approach at the ASGCT 2026 Annual Meeting Dispatch Bio has announced the presentation of new preclinical data highlighting its innovative SEND (Synthetic Efficacy eNableD) T cell armoring strategy at the upcoming American Society…
Mundipharma Reports Positive Phase III ReSPECT Topline Results for ▼REZZAYO (rezafungin) in Preventing Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Patients Mundipharma has announced encouraging topline results from its pivotal Phase III ReSPECT clinical trial, highlighting the potential of…
Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials Taiho Oncology, Inc., together with Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, has announced a key regulatory milestone in the development of its…
Johnson & Johnson Initiates Pivotal Head-to-Head Trial of Pulsed Field Ablation in Persistent Atrial Fibrillation Johnson & Johnson has announced the initiation of a landmark clinical study aimed at advancing the scientific understanding of pulsed field ablation (PFA), a rapidly…
Genentech Collaborates with Damon Wayans and diaTribe to Raise Awareness of Diabetes-Related Vision Loss Through ‘All Eyes on DME’ Campaign Genentech, a member of the Roche Group, has introduced a new awareness initiative aimed at addressing one of the most…
Reflow Medical Unveils U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters Reflow Medical, Inc. has announced the U.S. commercial launch of its next-generation Cora Flex® and Cora Force® Torqueable Microcatheters, marking a significant expansion of its coronary…
New AMRA Study Links Muscle Composition to Elevated Risk of Chronic Kidney Disease and Increased Mortality AMRA Medical has released new research shedding light on an important and previously underappreciated factor influencing outcomes in patients with Chronic Kidney Disease. The…
CatalYm Initiates Phase 2/3 Trial of Visugromab in Cancer Cachexia with First Patient Dosed CatalYm has announced an important milestone in its clinical development pipeline with the dosing of the first patient in its pivotal Phase 2/3 VINCIT trial (Visugromab…
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for neurological and metabolic disorders, has announced promising results from a…
As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug Administration to accelerate the review of psychedelic-based therapies signals a…
AV Laboratories Transforms IVF Science into Breakthrough Skin Longevity Innovations AV Laboratories is positioning itself at the forefront of a new era in skincare by bringing together decades of advanced biotechnology research and translating it into clinically inspired formulations designed…
Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced today that four scientific abstracts featuring its lead checkpoint inhibitor…